FindTrial
Sign In

A pilot: efficacy and safety of using combination of microneedle radiofrequency combination with polynucleotides compared with fractional microneedle radiofrequency for the treatment of melasma in Asians

A pilot: efficacy and safety of using combination of microneedle radiofrequency combination with polynucleotides compared with fractional microneedle radiofrequency for the treatment of melasma in Asians

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20210804002
Enrollment
30
Registered
2021-08-04
Start date
2020-12-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma melasma

Interventions

Patients with melasma
Treatment
melasma

Sponsors

IDS Medical Systems (Thailand) Co.,Ltd.
Lead Sponsor
GFN GROUP COMPANY LIMITED
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. having melasma both cheeks 2. older than or 18 years old

Exclusion criteria

Exclusion criteria: 1. history of allergy of anestheic cream 2. history of allergy of polypeptide serum 3. history of infection at face

Design outcomes

Primary

MeasureTime frame
darkness at 1, 2, 3, 6 months after treatment mexameter,Melasma area and severity socre at 1, 2, 3, 6 months after treatment masi score—

Secondary

MeasureTime frame
Average melanin at 1, 2, 3, 6 months after treatment Antera,Patient improvement score at 1, 2, 3, 6 months after treatment Quartile scale,Physician improvement score at 1, 2, 3, 6 months after treatment Quartile scale—

Countries

Thailand

Contacts

Public ContactRungsima WANITPHAKDEEDECHA

Mahidol university

pennpak@gmail.com0816406300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026